Brooklyn ImmunoTherapeutics, Inc.
(NYSE Amex Equities : BTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -1.39%43.850.9%$1523.47m
ABBVAbbVie, Inc. -0.39%107.661.9%$991.05m
JNJJohnson & Johnson -0.36%164.620.7%$987.18m
MRKMerck & Co., Inc. -0.50%71.610.7%$796.28m
LLYEli Lilly & Co. -0.47%229.961.1%$594.20m
BMYBristol-Myers Squibb Co. 0.03%61.251.0%$551.71m
AZNAstraZeneca Plc -1.84%55.561.0%$261.07m
NVSNovartis AG -1.08%83.470.2%$168.99m
SNYSanofi 0.39%48.380.2%$137.69m
GSKGlaxoSmithKline Plc -0.44%38.940.2%$122.91m
RPRXRoyalty Pharma Plc 0.31%38.500.1%$119.08m
NVONovo Nordisk A/S -0.94%101.420.1%$109.34m
VTRSViatris, Inc. -0.88%13.570.0%$109.22m
RGENRepligen Corp. 2.34%306.906.8%$102.98m
APLSApellis Pharmaceuticals, Inc. 0.62%34.210.0%$96.93m

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.